Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

LumaCina announces availability of Oral Morphine pain medication for New Zealanders

PERTH, Australia and MIAMI, May 31, 2024 /PRNewswire/ -- LumaCina, the pharmaceutical supplier and marketing division ofBridgewest Perth Pharma announce new production of Oral Morphine to meet critical drug shortage inNew Zealand. The shortfall of Oral Morphine has become increasingly concerning...

2024-05-31 05:17 2514

Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024

SAN JOSE, Calif., May 30, 2024 /PRNewswire/ -- Teikoku Pharma USA (TPU) announced today that the NMPA (National Medical Products Administration) has approved Lidoderm® ("lidocaine 5% patch as lidocaine cataplasms") for the treatment of Post Herpetic Neuralgia (PHN) inChina. TPU entered into an e...

2024-05-30 21:15 2998

OBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases

SHANGHAI, May 30, 2024 /PRNewswire/ -- On May 23, OBiO Technology, a world leading contract development and manufacturing organization for cell and gene therapy, officially launched the "Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases" ...

2024-05-30 21:00 2649

OBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases

Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

SHANGHAI, May 30, 2024 /PRNewswire/ -- JW (Cayman) Therapeutics Co. Ltd (the "Company" or "JW Therapeutics", together with its subsidiaries, the "Group"), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, pres...

2024-05-30 18:10 4458

Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone

SHENZHEN, China, May 30, 2024 /PRNewswire/ -- On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products Administration, ap...

2024-05-30 17:09 2201

Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

HEIDELBERG, Germany , May 29, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) for clinical tr...

2024-05-30 08:00 1822

Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata

* Once-daily topical treatment of mild / moderate alopecia areata (AA) with 1% STS-01 met the primary efficacy endpoint of >30% Severity of Alopecia Tool (SALT) score improvement compared to patients receiving placebo (p<0.0096) * Multiple secondary endpoints met with significant total hair re...

2024-05-30 07:05 5189

AVELOS THERAPEUTICS ANNOUNCES KRW 17 BILLION SERIES B FUNDING ROUND, SURPASSING KRW 30 BILLION TOTAL RAISED

Stassets Investment Leads Round with Major Contribution, Joined by LSK Investment and Shinhan Capital Investment Provides Crucial Resources for Company's Focus on Developing Small Molecule Synthetic New Drugs in Synthetic Lethality, DNA Damage Response, and Cell Cycle Sectors First-In-Class AD1...

2024-05-29 20:00 3036

Veritas Genetics at the forefront of genomic screening with new studies presented at the European Society of Human Genetics Conference - ESHG 2024

* Veritas will present two pioneering studies at the European Society of Human Genetics Conference, inBerlin from June 1 to June 4. With a focus on elective genomic screening and newborn genomic screening, Veritas aims to set new standards in preventive medicine. * The Conference, now in its...

2024-05-29 17:55 3076

Onconic Therapeutics Announces Positive Phase 3 Results for JAQBO at Digestive Diseases Week 2024

SEOUL, South Korea and WASHINGTON, May 29, 2024 /PRNewswire/ -- Onconic Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for oncology and gastrointestinal disorders, announced today the results of its Phase 3 ZERO-1 study of JAQBO (zastaprazan...

2024-05-29 17:35 3373

Frost & Sullivan Reported The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics

SHANGHAI, May 29, 2024 /PRNewswire/ -- Recently, Frost & Sullivan released the report "The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics". I. CDMOs are advancing the biopharmaceutical industry with superior biomanufacturing capabilities...

2024-05-29 14:08 2484

Frost & Sullivan Reported The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics

Shanghai Customs introduces measures to facilitate cross-border trade

SHANGHAI, May 28, 2024 /PRNewswire/ -- A news report from english.shanghai.gov.cn: To better facilitate cross-border trade, Shanghai Customs has introduced 36 measures with a focus on enhancing the experience for businesses. Here are some highlights: 1. Streamlining Customs Procedures: These me...

2024-05-29 11:14 2039

Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD

KYOTO, Japan, May 28, 2024 /PRNewswire/ -- Rege Nephro CO., Ltd. ( https://www.regenephro.co.jp/en ) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a dev...

2024-05-28 23:00 2630

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

* Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. * Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innova...

2024-05-28 19:00 2477

Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies

* Synergistic collaboration to revolutionize age-related therapies worldwide * Deal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and enabling technologies, today announced an e...

2024-05-28 19:00 2078

Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA

SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2024-05-28 08:00 3958

Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome

Highlights: * Statistically significant improvement from baseline assessed by both clinicians and caregivers in all four efficacy measures specifically designed for Pitt Hopkins syndrome (Wilcoxon signed rank test p<0.05) * Clinician and caregiver global efficacy measures showed a level of i...

2024-05-27 18:00 2725

Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine "Curcumin" as Effective Treatment for Dyspepsia as Modern Antacids

Chula Medicine in collaboration with the Department of Thai Traditional and Alternative Medicine and Gastroenterologists from local medical schools proves thatThai curcumin can help treat dyspepsia as effectively as ant...

2024-05-27 11:00 3988

Chula Medicine Joins Forces with the Department of Thai Traditional and Alternative Medicine to Determine

Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

- Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-powered ICI response prediction models for NSCLC, demonstrating the impact of Lunit SCOPE suite on precision oncology SEOUL, South Korea, May 24, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leadin...

2024-05-24 22:07 6375

Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting

SHANGHAI, May 24, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple advanced solid tumors, which will be reported as an oral pre...

2024-05-24 22:00 6087

1 ... 117 118 119120121 122 123 ... 339